

Neuland Laboratories Limited  
Sanali Info Park, 'A' Block,  
Ground Floor, 8-2-120/113  
Road No. 2, Banjara Hills  
Hyderabad - 500 034.  
Telangana, India.

Tel: 040 30211600 / 23551081  
Fax: 040 30211602  
Email: neuland@neulandlabs.com  
www.neulandlabs.com

August 14, 2017

To  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai - 400 001

To  
The National Stock Exchange of India Ltd  
Exchange Plaza,  
Bandra Kurla Complex, Bandra (E)  
Mumbai - 400 001

Scrip Code: 524558

Scrip Code: NEULANDLAB  
Series: EQ

Dear Sir,

**Sub: Board Meeting for approval of Unaudited Financial Results under Reg.33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 to be held on or before September 14, 2017**

**Ref: SEBI Circular No. CIR/CFD/FAC/62/2016 Dated July 5, 2016 ("SEBI Circular")**

We refer to the afore-mentioned SEBI Circular dated July 5, 2016 granting extension of one month, i.e., until September 14, 2017 for submitting the Financial Results for the quarter ended June 30, 2017 to the listed entities to facilitate smooth transition during the first year of Ind-AS implementation.

We would like to inform you that the Company proposes to convene a meeting of the Board of Directors for approval of Unaudited Financial Results for the quarter ended June 30, 2017 on or before September 14, 2017 by availing the extension granted by SEBI vide the afore-mentioned Circular.

The Company shall intimate the date of the Board Meeting for approval of Unaudited Financial Results for the quarter ended June 30, 2017 and the dates for Closure of Trading Window for dealing in the Company's securities upon finalizing the Board Meeting date.

This is for your information and records.

Thanking you,

Yours sincerely,  
For Neuland Laboratories Limited



**Sarada Bhamidipati**  
**Company Secretary**  
**M No: 27854**